Background. Standard liver function parameter levels and tumor indices were analyzed using Network
Introduction
Previous work has shown that 2 general processes contribute to HCC prognosis. They are liver damage indices, such as bilirubin, prothrombin time and AST , as well as tumor biology indices, such as tumor size, tumor number, presence of PVT and blood AFP levels (1) (2) (3) (4) (5) . These 2 general processes may affect one another (6) (7) (8) . Non disease factors such as gender and age can also influence HCC outcomes (9) (10) , suggesting that any individual disease parameter needs to be considered within a total clinical context. Prognostically significant factors may actually function in part through interaction with multiple other tumor and host parameters, as the basis for this context. This context might even provide patient personalization to individually measured parameters. Thus, a given level of bilirubin or tumor diameter might have a different significance in different total clinical contexts.
We thus considered standard liver function parameter levels and commonly assessed tumor indices, within the total context of the relationships between all of the parameters together of individual patients. The net result, obtained using a large cohort of Chinese HCC patients in Taiwan (n=4139) in a training set was that unmanageably complex individual patient parameter relationships were captured in just 9 relationship patterns, and were significantly related to disease outcome (11) . Within these 9 relationship patterns, there were 2 distinct general sub-sets of parameter level and relationship patterns, closeness or large distance from them being associated with significantly different tumor masses. We called these two phenotype subgroups of HCC patients with different clinical characteristics 'S' and 'L', for 'small' and 'large' tumor mass. However, survival data was not available for that analysis. In the current paper, we have used an Italian database of 1619 HCC patients with known survival outcomes, to validate that these 2 characteristic pattern sets and the personalized characterization of the closeness and differences from these clinical patterns, can also provide significantly different tumor mass outcomes and that patients with these two different phenotype and clinical relationship patterns have significantly different survival outcomes.
Methods
Data collection. We retrospectively analyzed prospectively-collected data in the Italian Liver Cancer (ITA.LI.CA) study group database of HCC patients accrued at 11 centers (12) . 2773 newly diagnosed HCC patients had full baseline parameter data, including radiology of maximum tumor diameter (MTD), number of tumor nodules and presence of PVT; demographics (gender, age, alcohol history, presence of hepatitis B or C); blood counts (hemoglobin, white cells, platelets, prothrombin time); blood AFP and routine liver function tests, (total bilirubin, AST, ALKP, GGTP, albumin). ITA.LI.CA database management conforms to Italian legislation on privacy and this study conforms to the ethical guidelines of the Declaration of Helsinki. Approval for the study on de-identified patients was obtained by the Institutional Review Board of participating centers.
Data processing.
The clinical parameter data were processed exactly as previously (11, 13) . The data processing summary and parameter-relationship pattern based classification model is shown in Fig 1. In the training set data from Taiwan (Fig. 1a) , the screening "raw" clinical data was converted into 4139 individual patient profiles (Fig. 1b) . In designing these profiles we first used graph-theory algorithm to identify pairs of collectively most correlated liver function and tumor growth-related parameters (platelets/AFP, AST/ALT and bilirubin/INR), each pair being used as one component of the individual clinical profiles. This step incorporated explicitly the strongest inter-relationships (pairwise correlations) within the data and thus reduced the number of parameter-parameter relationships to be considered. The paired parameter values were dichotomized into high (H) and low (L) using terciles (L corresponded to 2/3 of patient's cohort with the lowest paired parameter values, H to the upper 1/3). This approach allowed direct combination with the rest of the clinical data (demographic, hepatitis, portal vein thrombosis) in a unified quantitative scheme. All individual clinical profiles were collected into 10-partite network K 10 ( Fig.1c) with edges weighted by the cooccurrence frequencies quantifying all relationships between all parameters. This study network was then used to generate reference relationship patterns, relative to which we compared the actual individual clinical profiles, using specific algorithm (11, 13) . It was found (Fig.1d ) that the training set network was a weighted combination of 19 reference relationship patterns. By definition, these 19 reference relationship patterns collect independently all pairwise context relationships (such as when males have PVT present, when the PVT is present with AFP and platelet levels in the high, upper tercile subgroup etc., covering the complete set of all 45 pairwise relationships between the 10 parameter groups (Fig.1a) . We collected into the respective reference relationship patterns those pairwise parameter relationship patterns, which were observed in the study data with identical frequencies. This guarantees that results are independent of the parameter ordering in the clinical profile. In the final step of the clinical data transformation, we compared actual individual clinical profiles for each patient with these reference relationship patterns and characterized the closeness 5 between them by counting differences (see Fig.1e ). In this way, we arrived at our new characterization of the context relationships in the study data, quantified by the set of 19 "distances" from respective ideal reference clinical relationship patterns. We previously found, using the variable selection in combination with the logistic regression least squares optimization, that distances from only 9 out of these 19 reference relationship patterns are significantly associated with tumor mass (Fig. 1d) as the HCC outcome parameter.
For the purpose of this validation study, we converted the data from this cohort of 1619 HCC patients into their individual clinical profiles identically to the training set data processing. We then computed the distances of every individual clinical profile from 9 significant reference relationship patterns ( tumor mass differences between these two HCC tumor phenotypes, identified by our relationship pattern analysis in the Chinese patient training dataset.
Results

Independent validation of S and L clinical phenotyping
Although the difference of means was highly statistically significant, there was still significant overlap in the distribution of the tumor masses in the 2 groups. The overlap reflects the complexity of the HCC phenotype together with the unknown point on the course of the HCC development at the point of any individual patient diagnosis. By inspecting these distributions separately in S and L phenotype subgroups we found that probability of finding the same tumor mass in the 2 HCC groups was significantly different (Fig. 2c , differences between the probabilities are larger than 2 times 95% confidence interval of the respective probability estimates). We therefore conclude that, for a given tumor mass, patients from the S group are significantly more likely to be in a more advanced phase of HCC progression than in the L group.
Survival was also analyzed in two ways. First, we tested the statistical significance of the differences in The relationships between tumor mass and both internal tumor factors (AFP) and liver factors Following these novel ideas, we therefore examined trends revealed by the moving-average processing for AST and GGTP with respect to increasing tumor mass. They showed remarkable similarities to the trends for bilirubin (Figs 3b and 3c ).
These results also showed that beyond a certain small tumor mass, continued tumor growth was not accompanied by increased evidence for tumor damage. In this multi-variable context, it is interesting that the examination of AFP trends showed increased levels with increasing tumor mass and was comparable for both S and L groups. AFP thus appears to monitor tumor growth through its full range, 
AFP relationships
Given the finding of AFP as a monitor of HCC growth, above, we next analyzed the typical levels of liver function parameters for patients with comparable AFP levels, separately for S and L phenotype groups. We analyzed patterns in bilirubin, tumor numbers and survival with respect to AFP levels (Fig. 4) . We found that tumor tumors increased with increasing AFP levels in both phenotypes. However, there was typically a smaller number of tumors in S compared with L phenotype, for patients with comparable AFP levels (Fig. 4A) . Furthermore, beyond AFP log 2.5 levels, tumor numbers increased at a greater rate in L patients than in S.
Thus, the increase in tumor mass from AFP log 0 to 2.5 in Fig 3 above , is likely due to increase in tumor size alone, but above this AFP level, the increase in tumor mass also has a contribution from increased number of tumor nodules, mainly in L. The increase in numbers of tumors in S was only modest. Increasing AFP levels were associated with decreasing survival. Thus, for a given similarity of survival, L patients had higher AFP than S patients (Fig. 4B) . Given the importance of both liver and tumor factors in HCC, we next plotted the trends in bilirubin levels as a function of increasing AFP levels. We found incoherency between bilirubin and AFP typical levels up to log AFP 2.0. Thereafter, this trend continued for S patients, but not L, in whom increasing AFP was followed by increasing bilirubin levels (Fig. 4D) . In Fig 3A, in S patients. This transition in AFP levels around log 2 corresponds to the change in the rate of increase per unit of tumor mass and also to the point at which bilirubin/tumor mass level changes diverged between S and L in Fig. 3 .
Platelet relationships.
After our initial analysis of complete correlations between all parameters (Methods), platelets and AFP were part of the set of 4 pairs with highest correlations. Examination of patterns of trends between platelets and other parameter were examined (Fig. 5) . We found no correlation of platelets with tumor mass or number for S patients. However, for L patients there was a linear trend between typical platelet values and tumor mass or number of nodules in L patients. We found a U-shaped pattern in the trends for platelets with increasing AFP, with a turning point at log AFP 1.5 to 2. In addition, platelet levels were systematically lower in S than L. This transition point also corresponds to transitions in other parameters. In the majority of the AFP range, from log 1.5 to log 3 levels, there was an increase in platelets with increase in AFP. At the highest AFP levels at >log 2.5, where bilirubin levels also are increasing (Fig. 4) , the platelets start to decrease, consistent with the bilirubin/platelet relationship of liver failure. 
Discussion
We have previously used a network phenotyping strategy (NPS) on a large cohort of Chinese HCC patients, to show that analysis of parameter relationship patterns could identify 2 sets of HCC patient phenotypes, called S and L. The results showed that if the parameter values were considered in the context of all other parameters, that for a given tumor mass, we could identify 2 possible sets of clinical phenotypic patterns. Survival data was not available for that analysis. We have now extended that initial study, by examining whether this approach could be used to examine a large and completely different HCC cohort amongst another ethnic patient HCC group, using the identical method of data processing and the quantitative model. We again found that the total cohort could be cleanly separated into S and L phenotypes, each associated with significantly different tumor masses and survival.
Main findings of this paper include the relationships between various parameter patterns and total tumor mass (Fig. 2) . Three parameter trends in relation to tumor mass showed distinct differences between S and L: Trends for bilirubin, AST and GGTP showed an increase with increasing tumor mass for L, but not for S patients, beyond limited tumor mass, However, the trends for AFP were different, since there was a general non-linear increase in AFP with tumor mass for both S and L patients. We interpret this to signify the direct importance of AFP in growth of both S and L tumors. By contrast, we suppose that involvement of bilirubin, AST and GGTP with tumor mass is more indirect. Thus, AFP could be a mediator of internally-derived growth of HCCs (oncogenes, growth factors), whether of S or L phenotype. By contrast, the other 3 liver parameters might reflect the tumor micro-environment that permits or modulates HCC growth and behavior. We found that trends for bilirubin, AST and GGTP were all higher for the larger and more aggressive HCC L phenotype, that were associated with shorter survival than S phenotype patients. This NPS approach thus synthesizes and integrates both liver and tumor factors.
The analysis reveals both pattern and complexity in HCC phenotypes. Both liver and tumor factors are well-described in HCC prognosis. Our relationship pattern based processing of the data permitted us to discern 2 distinct clinical HCC phenotypes. Inspecting typical trends between different parameters, we found increasing trends in L phenotypes for several parameters, but constancy in parameter trends for S phenotype, which suggests some possible mechanistic interpretations. Most HCCs arise on the basis of hepatic inflammation with some degree of associated cirrhosis (14, 15, 16) , and is consistent with elevated bilirubin, AST and GGTP for the S and L tumors. The portal hypertension and splenomegaly associated thrombocytopenia appeared mainly as a feature of S tumors, reflecting small HCC development in cirrhosis. As S tumors grew, they did not appear to further worsen the liver function parameters, possibly due to their significantly smaller size compared to L tumors. The parameter trends were more complex in L tumors, likely due to multiple factors, including hepatic inflammation and endogenous tumor factors. Unlike S, the L phenotype patients predominantly did not have thrombocytopenia. We hypothesize than in L, unlike S patients, the known platelet-derived tumor growth factors (17) (18) (19) (20) (21) (22) (23) (24) and inflammation-associated cytokines (25, 26) may play a role in the expansion of the growing tumor mass. There is an inverse relationship between bilirubin and platelet levels in portal hypertension, and our patients were no exception (Fig. 5C ). However, there are also other causes of elevated bilirubin levels, which must be involved to explain the increasing bilirubin levels associated with large tumors seen in 
